CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

chimeric antigen receptor
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
A Revised CAR T for Lymphoma Has Fewer Side Effects
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 
Researchers Build a Cancer Immunotherapy Without Immune Cells
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena | Nov 13, 2017
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 
FDA Approves Second CAR T-Cell Therapy
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 
Another CAR-T IPO
Another CAR-T IPO
Jef Akst | Apr 6, 2015
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.
To Each His Own
To Each His Own
Mary Beth Aberlin | Apr 1, 2015
Cancer treatment becomes more and more personal.